SEARCH

SEARCH BY CITATION

References

  • 1
    Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980; 55: 4348.
  • 2
    Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology 1990; 12: 110610.
  • 3
    Lane JT, Mack-Shipman LR, Anderson JC et al. Comparison of CT and dual-energy DEXA using a modified trunk compartment in the measurement of abdominal fat. Endocrine 2005; 27: 2959.
  • 4
    Molarius A, Seidell JC, Visscher TL, Hofman A. Misclassification of high-risk older subjects using waist action levels established for young and middle-aged adults: Results from the Rotterdam Study. J. Am. Geriatr. Soc. 2000; 48: 163845.
  • 5
    Caballero AE. Metabolic and vascular abnormalities in subjects at risk for type 2 diabetes: The early start of a dangerous situation. Arch. Med. Res. 2005; 36: 2419.
  • 6
    Herva A, Laitinen J, Miettunen J et al. Obesity and depression: Results from the longitudinal Northern Finland 1966 Birth Cohort Study. Int J Obes (Lond.) 2006; 3: 5207.
  • 7
    Bastarolo D, Battaggia A, Blengio G et al. [A cross-sectional survey to evaluate the cardiovascular risk profile in subjects referred to the Verona-ASL 20 general practitioners]. Ital. Heart J. Suppl. 2005; 6: 3827.
  • 8
    Wang CL, Hsieh MC, Hsin SC et al. The hOGG1 Ser (326) Cys gene polymorphism is associated with decreased insulin sensitivity in subjects with normal glucose tolerance. J. Hum. Genet. 2006; 51: 1248.
  • 9
    Mari A, Pacini G, Brazzale AR, Ahren B. Comparative evaluation of simple insulin sensitivity methods based on oral glucose tolerance test. Diabetologia 2005; 48: 74851.
  • 10
    Schwimmer JB, Behling C, Newbury R et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005; 42: 6419.
  • 11
    Laurin J. Motion: All patients with NASH need to have a liver biopsy: Arguments against the motion. Can. J. Gastroenterol. 2002; 16: 7226.
  • 12
    Al-Habsi KR, Johnson EH, Kadim IT et al. Comparative effects of low levels of dietary cobalt and parenteral injections of vitamin B12 on body dimensions in different breeds of Omani goats. Small Ruminant Research 2006; 66: 24452.
  • 13
    Silfen ME, Manibo AM, Ferin M, McMahon DJ, Levine LS, Oberfield SE. Elevated free IGF-I levels in prepubertal Hispanic girls with premature adrenarche: Relationship with hyperandrogenism and insulin sensitivity. J. Clin. Endocrinol. Metab. 2002; 87: 398403.
  • 14
    Prentice AM. The emerging epidemic of obesity in developing countries. Int. J. Epidemiol. 2006; 35: 939.
  • 15
    Weidmann P, De Courten M, Boehlen L, Shaw S. The pathogenesis of hypertension in obese subjects. Drugs 1993; 46: 197208.
  • 16
    Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 12: 91100.
  • 17
    Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 3739.
  • 18
    Garcia-Monzon C, Martin-Perez E, Iacono OL et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J. Hepatol. 2000; 33: 71624.
  • 19
    Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol. 2003; 98: 96067.
    Direct Link:
  • 20
    Pagano G, Pacini G, Musso G et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association. Hepatology 2002; 35: 36772.
  • 21
    Day CP. Non-alcoholic steatohepatitis (NASH): Where are we now and where are we going? Gut 2002; 50: 5858.
  • 22
    Zatloukal K, Stumptner C, Fuchsbichler A et al. The keratin cytoskeleton in liver diseases. J. Pathol. 2004; 204: 36776.
  • 23
    Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am. J. Gastroenterol. 2004; 99: 2928.
    Direct Link:
  • 24
    Gupte P, Amarapurkar D, Agal S et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J. Gastroenterol. Hepatol. 2004; 19: 8548.
  • 25
    Reynet C, Kahn CR. Rad: A member of the Ras family overexpressed in muscle of type II diabetic humans. Science 1993; 262: 14414.
  • 26
    Saibara T, Onishi S, Ogawa Y, Yoshida S, Enzan H. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. Lancet 1999; 353: 1802.
  • 27
    Caldwell SH, Chang CY, Nakamoto RK, Krugner-Higby L. Mitochondria in nonalcoholic fatty liver disease. Clin. Liver Dis. 2004; 8: 595617.
  • 28
    Lima FB, Thies RS, Garvey WT. Glucose and insulin regulate insulin sensitivity in primary cultured adipocytes without affecting insulin receptor kinase activity. Endocrinology 1991; 128: 241526.
  • 29
    Dey D, Mukherjee M, Basu D et al. Inhibition of insulin receptor gene expression and insulin signaling by fatty acid: Interplay of PKC isoforms therein. Cell. Physiol. Biochem. 2005; 16: 21728.
  • 30
    Lofgren P, Van Harmelen V, Reynisdottir S et al. Secretion of tumor necrosis factor-alpha shows a strong relationship to insulin-stimulated glucose transport in human adipose tissue. Diabetes 2000; 49: 68892.
  • 31
    Jung KJ, Kim JY, Zou Y, Kim YJ, Yu BP, Chung HY. Effect of short-term, low dose aspirin supplementation on the activation of pro-inflammatory NF-kappaB in aged rats. Mech. Ageing Dev. 2006; 12: 22330.
  • 32
    Pagano C, Dorigo A, Nisoli E et al. Role of insulin and free fatty acids in the regulation of ob gene expression and plasma leptin in normal rats. Obes. Res. 2004; 12: 20629.
  • 33
    Brix AE, Elgavish A, Nagy TR, Gower BA, Rhead WJ, Wood PA. Evaluation of liver fatty acid oxidation in the leptin-deficient obese mouse. Mol. Genet. Metab. 2002; 75: 21926.
  • 34
    Aleffi S, Petrai I, Bertolani C et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 2005; 42: 133948.
  • 35
    Pajvani UB, Scherer PE. Adiponectin: Systemic contributor to insulin sensitivity. Curr. Diab. Rep. 2003; 3: 20713.
  • 36
    Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38: 41319.
  • 37
    Schattenberg JM, Wang Y, Singh R, Rigoli RM, Czaja MJ. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J. Biol. Chem. 2005; 280: 988794.
  • 38
    Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am. J. Physiol. Gastrointest. Liver Physiol. 2001; 281: G11359.
  • 39
    Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 12833.
  • 40
    Duivenvoorden I, Teusink B, Rensen PC et al. Acute inhibition of hepatic beta-oxidation in APOE*3Leiden mice does not affect hepatic VLDL secretion or insulin sensitivity. J. Lipid Res. 2005; 46: 98893.
  • 41
    Yesilova Z, Ozata M, Oktenli C et al. Increased acylation stimulating protein concentrations in nonalcoholic fatty liver disease are associated with insulin resistance. Am. J. Gastroenterol. 2005; 100: 8429.
    Direct Link:
  • 42
    Mensenkamp AR, Van Luyn MJ, Van Goor H et al. Hepatic lipid accumulation, altered very low density lipoprotein formation and apolipoprotein E deposition in apolipoprotein E3-Leiden transgenic mice. J. Hepatol. 2000; 33: 18998.
  • 43
    Larsson SL, Skogsberg J, Bjorkegren J. The low density lipoprotein receptor prevents secretion of dense apoB100-containing lipoproteins from the liver. J. Biol. Chem. 2004; 279: 8316.
  • 44
    Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002; 35: 898904.
  • 45
    Francis GA, Li G, Casey R et al. Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Med. Genet. 2006; 7: 3.
  • 46
    Udtke A, Genschel J, Brabant G et al. Hepatic steatosis in Dunnigan-type familial partial lipodystrophy. Am. J. Gastroenterol. 2005; 100: 221824.
    Direct Link:
  • 47
    Ono H, Shimano H, Katagiri H et al. Hepatic Akt activation induces marked hypoglycemia, hepatomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement. Diabetes 2003; 52: 290513.
  • 48
    Simha V, Szczepaniak LS, Wagner AJ, DePaoli AM, Garg A. Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care 2003; 26: 3035.
  • 49
    Sakaida I, Okita K. The role of oxidative stress in NASH and fatty liver model. Hepatol. Res. 2005; 33: 12831.
  • 50
    Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: A pilot study. JAMA 1999; 282: 165964.
  • 51
    Schneider AR, Kraut C, Lindenthal B, Braden B, Caspary WF, Stein J. Total body metabolism of 13C-octanoic acid is preserved in patients with non-alcoholic steatohepatitis, but differs between women and men. Eur. J. Gastroenterol. Hepatol. 2005; 17:11814.
  • 52
    Uchino S, Yamaguchi Y, Furuhashi T et al. Steatotic liver allografts up-regulate UCP-2 expression and suffer necrosis in rats. J. Surg. Res. 2004; 120: 7382.
  • 53
    Nozaki Y, Saibara T, Nemoto Y et al. Polymorphisms of interleukin-1 beta and beta 3-adrenergic receptor in Japanese patients with nonalcoholic steatohepatitis. Alcohol. Clin. Exp. Res. 2004; 28: 106S110S.
  • 54
    Fan JG, Xu ZJ, Wang GL, Ding XD, Tian LY, Zheng XY. Change of serum endotoxin level in the progress of nonalcoholic steatohepatitis in rats. Zhonghua Gan Zang Bing Za Zhi 2003; 11: 736.
  • 55
    Morton GJ, Gelling RW, Niswender KD, Morrison CD, Rhodes CJ, Schwartz MW. Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase signaling in mediobasal hypothalamic neurons. Cell Metab. 2005; 2: 41120.
  • 56
    Mutze J, Roth J, Gerstberger R, Matsumura K, Hubschle T. Immunohistochemical evidence of functional leptin receptor expression in neuronal and endothelial cells of the rat brain. Neurosci. Lett. 2006; 394: 10510.
  • 57
    Zhang SN, Xu FQ, Huang ZQ, Zeng ZY, Yuan SZ. [The effect of recombinant adenovirus encoding antisense MAT1 on cell cycle of human pancreatic cancer cells BxPC-3]. Zhonghua Yi Xue Za Zhi 2005; 85: 134851.
  • 58
    Oz HS, Im HJ, Chen TS, De Villiers WJ, McClain CJ. Glutathione-enhancing agents protect against steatohepatitis in a dietary model. J. Biochem. Mol. Toxicol. 2006; 20: 3947.
  • 59
    Sanyal AJ. Mechanisms of disease: Pathogenesis of nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2005; 2: 4653.
  • 60
    Kleiner DE, Brunt EM, Van Natta M et al., Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 4: 131321.
  • 61
    Ratziu V, Charlotte F, Heurtier A et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898906.
  • 62
    Allard JP. Other disease associations with non-alcoholic fatty liver disease (NAFLD). Best Pract. Res. Clin. Gastroenterol. 2002; 16: 78395.
  • 63
    Dong G, Liang L, Zou C. Congenital generalized lipodystrophy in a 4 year old Chinese girl. Indian Pediatr. 2005; 42: 10368.
  • 64
    Bolding J, Wratchford T, Perkins K, Ogershok P. Prevalence of obesity, acanthosis nigricans and hyperinsulinemia in an adolescent clinic. W V Med. J. 2005; 101: 11215.
  • 65
    Basaran C, Karcaaltincaba M, Akata D et al. Fat-containing lesions of the liver: Cross-sectional imaging findings with emphasis on MRI. AJR 2005; 184: 110310.
  • 66
    Saadeh S, Younossi ZM, Remer EM et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 74550.
  • 67
    Mortele KJ, Ros PR. Imaging of diffuse liver disease. Semin. Liver Dis. 2001; 2: 195212.
  • 68
    Focht BC, Rejeski WJ, Ambrosius WT, Katula JA, Messier SP. Exercise, self-efficacy, and mobility performance in overweight and obese older adults with knee osteoarthritis. Arthritis Rheum. 2005; 53: 65965.
  • 69
    Fowler SB, Moussouttas M, Mancini B. Metabolic syndrome: Contributing factors and treatment strategies. J. Neurosci. Nurs. 2005; 37: 22023.
  • 70
    Spieth LE, Harnish JD, Lenders CM et al. A low-glycemic index diet in the treatment of pediatric obesity. Arch. Pediatr. Adolesc. Med. 2000; 154: 94751.
  • 71
    Wilson DM. Progress in the treatment of childhood diabetes mellitus and obesity. J. Pediatr. Endocrinol. Metab. 2002; 15: 7459.
  • 72
    Nelson RH, Miles JM. The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes. Expert Opin. Pharmacother. 2005; 6: 248391.
  • 73
    Harp JB. Orlistat for the long-term treatment of obesity. Drugs Today 1999; 35: 13945.
  • 74
    Schirmer B. Laparoscopic bariatric surgery. Surg. Endosc 2006; 2: S45055.
  • 75
    Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J. Clin. Gastroenterol. 2006; 40: S5S10.
  • 76
    Shaffer EA. Bariatric surgery: A promising solution for nonalcoholic steatohepatitis in the very obese. J. Clin. Gastroenterol. 2006; 40: S4450.
  • 77
    Rossner S. [Should obesity in the elderly be treated? Sparse scientific evidence to support treatment of overweight in this age group]. Lakartidningen 2005; 102: 28568.
  • 78
    Albers MJ, Steyerberg EW, Hazebroek FW et al. Glutamine supplementation of parenteral nutrition does not improve intestinal permeability, nitrogen balance, or outcome in newborns and infants undergoing digestive-tract surgery: Results from a double-blind, randomized, controlled trial. Ann. Surg. 2005; 241: 599606.
  • 79
    Ersoz G, Gunsar F, Karasu Z, Akay S, Batur Y, Akarca US. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. Turk. J. Gastroenterol. 2005; 16: 1248.
  • 80
    Shin SJ. Vitamin E modulates radiation-induced oxidative damage in mice fed a high-lipid diet. J. Biochem. Mol. Biol. 2003; 36: 19095.
  • 81
    Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 2005; 129: 894901.
  • 82
    Mendez-Sanchez N, Gonzalez V, Chavez-Tapia N, Ramos MH, Uribe M. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial. Ann. Hepatol. 2004; 3: 1081.
  • 83
    Wu D, Cederbaum AI. Opposite action of S-adenosylmethionine and its metabolites on CYP2E1-mediated toxicity in pyrazole induced rat hepatocytes and HepG2, E47 cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2006; 290: G67484.
  • 84
    Medina J, Moreno-Otero R. Pathophysiological basis for antioxidant therapy in chronic liver disease. Drugs 2005; 65: 244561.
  • 85
    Angulo P. Current best treatment for non-alcoholic fatty liver disease. Expert Opin. Pharmacother. 2003; 4: 61123.
  • 86
    Carlo C, Daniela P, Giancarlo C. Iron depletion and response to interferon in chronic hepatitis C. Hepatogastroenterology 2003; 50: 146771.
  • 87
    Kimura F, Hayashi H, Yano M et al. Additional effect of low iron diet on iron reduction therapy by phlebotomy for chronic hepatitis C. Hepatogastroenterology 2005; 52: 5636.
  • 88
    Dormandy JA, Charbonnel B, Eckland DJ et al., PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005; 366: 127989.
  • 89
    Wong TY, Szeto CC, Chow KM, Leung CB, Lam CW, Li PK. Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Am. J. Kidney Dis. 2005; 46: 71319.
  • 90
    Guo L, Tabrizchi R. Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance. Pharmacol. Ther. 2006; 111: 14573.
  • 91
    Jessen N, Djurhuus CB, Jorgensen JO et al. Evidence against a role for insulin-signaling proteins PI 3-kinase and Akt in insulin resistance in human skeletal muscle induced by short-term GH infusion. Am. J. Physiol. Endocrinol. Metab. 2005; 288: E1949.
  • 92
    Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: A retrospective cohort study of adults with employer-sponsored health insurance. Clin. Ther. 2005; 27: 106473.
  • 93
    Langfort J, Viese M, Ploug T, Dela F. Time course of GLUT4 and AMPK protein expression in human skeletal muscle during one month of physical training. Scand. J. Med. Sci. Sports 2003; 13: 16974.
  • 94
    Christ-Roberts CY, Pratipanawatr T, Pratipanawatr W et al. Exercise training increases glycogen synthase activity and GLUT4 expression but not insulin signaling in overweight nondiabetic and type 2 diabetic subjects. Metabolism 2004; 53: 123342.
  • 95
    Arioglu E, Duncan-Morin J, Sebring N et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann. Intern. Med. 2000; 133: 26374.
  • 96
    Bugianesi E, Gentilcore E, Manini R et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am. J. Gastroenterol. 2005; 100: 108290.
    Direct Link:
  • 97
    Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Apridonidze T, He N, Nestler JE. Metformin therapy increases insulin-stimulated release of d-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2004; 89: 2429.
  • 98
    Gentilcore D, Bryant B, Wishart JM, Morris HA, Horowitz M, Jones KL. Acarbose attenuates the hypotensive response to sucrose and slows gastric emptying in the elderly. Am. J. Med. 2005; 118: 1289.
  • 99
    Penna IA, Canella PR, Reis RM, Silva de Sa MF, Ferriani RA. Acarbose in obese patients with polycystic ovarian syndrome: A double-blind, randomized, placebo-controlled study. Hum. Reprod. 2005; 20: 2396401.
  • 100
    Carracedo E. [Acarbose for the treatment of impaired glucose tolerance?]. Gac. Sanit. 2005; 19: 265.
  • 101
    Goke B, German Pioglitazone Study Group. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus. Treat. Endocrinol. 2002; 1: 32936.
  • 102
    Kok P, Kok SW, Buijs MM et al. Enhanced circadian ACTH release in obese premenopausal women: Reversal by short-term acipimox treatment. Am. J. Physiol. Endocrinol. Metab. 2004; 287: E84856.
  • 103
    Bruno S, Maisonneuve P, Castellana P et al. Incidence and risk factors for non-alcoholic steatohepatitis: Prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005; 330: 932.
  • 104
    Murata Y, Ogawa Y, Saibara T et al. Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: Determination of a suitable biopsy site for diagnosis. Oncol. Rep. 2003; 10: 97100.
  • 105
    Nishino M, Hayakawa K, Nakamura Y, Morimoto T, Mukaihara S. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: High frequency of involvement and rapid reversal after completion of tamoxifen therapy. AJR 2003; 180: 12934.
  • 106
    Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J. Hepatol. 1999; 31: 384.
  • 107
    Hay R, Tammi K, Ryffel B, Mihatsch MJ. Alterations in molecular structure of renal mitochondria associated with cyclosporine treatment. Clin. Nephrol. 1986; 25: S236.
  • 108
    Kerr C. Radiation sensitiser effective against liver disease. Lancet Oncol. 2006; 7: 19.
  • 109
    Iwasaki Y, Ikeda H, Araki Y et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006; 43: 5463.